European Commission logo
Deutsch Deutsch
CORDIS - Forschungsergebnisse der EU
CORDIS
Inhalt archiviert am 2024-06-18

European Modular Education and Training Programme in Safety Sciences for Medicines

Ziel

Background:
In current drug safety education and training in Europe, an integrative and translational approach is lacking. This shortfall has been identified by EUFEPS. The IMI (‘Strategic Research Agenda’), the FDA and the EMEA have also characterised this fact as a crucial gap in the education and training of scientists evaluating the safety of drug candidates and new medicines.

Scope and objectives:
We present a new and unique pan-European education and training network, which solves this shortfall by developing and establishing a comprehensive modular Education and Training Programme in Safety Sciences for Medicines (SafeSciMET). This programme will fulfil the needs of pharmaceutical industry, regulatory authorities and academia. The network, consisting of top institutes for drug safety education and research, proposes a new type, high quality and sustainable programme for education and training in Safety Sciences for Medicines (S2M). The tailor-made training modules will encompass the safety, ethical, regulatory and societal aspects in all phases of drug development, with emphasis on integrative, translational and 3Rs aspects of drug safety assessment. Individual safety professionals who wish to address specific knowledge gaps will be able to follow single modules. The modular set up also provides an excellent opportunity for following dedicated sub-sets of modules, to be accredited for Continuing Professional Development (CPD). Scientists successfully completing the full programme, including an integrative MSc-thesis, will be awarded with an accredited Master of Advanced Safety Sciences of Medicines (M4S2M). All training modules and procedures will be aligned with the Bologna process.

Principle learning outcomes are novel competences in translational safety sciences, leading to safety scientists who are able to perform holistic and critical evaluations of the safety of drug candidates and new medicines by linking of animal and patient data.

Wissenschaftliches Gebiet

Programm/Programme

Thema/Themen

Aufforderung zur Vorschlagseinreichung

IMI-JU-01-2008
Andere Projekte für diesen Aufruf anzeigen

Finanzierungsplan

JTI-CP-IMI - Joint Technology Initiatives - Collaborative Project (IMI)

Koordinator

F. HOFFMANN-LA ROCHE AG
EU-Beitrag
Keine Daten
Adresse
GRENZACHERSTRASSE 124
4070 Basel
Schweiz

Auf der Karte ansehen
Region
Schweiz/Suisse/Svizzera Nordwestschweiz Basel-Stadt
Aktivitätstyp
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Kontakt Verwaltung
Manfred Kansy (Dr.)
Hauptforscher
Manfred Kansy (Dr.)
Links
Gesamtkosten
Keine Daten

Beteiligte (32)

Diese Seite teilen

Herunterladen

Letzte Aktualisierung: 25 März 2022

Mein Booklet

Permalink: https://cordis.europa.eu/project/id/115012/de

European Union, 2024